Last reviewed · How we verify

Terlipressin acetate continuous infusion

BioVie Inc. · Phase 2 active Small molecule

Terlipressin acetate continuous infusion is a Small molecule drug developed by BioVie Inc.. It is currently in Phase 2 development. Also known as: Terlipressin.

At a glance

Generic nameTerlipressin acetate continuous infusion
Also known asTerlipressin
SponsorBioVie Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Terlipressin acetate continuous infusion

What is Terlipressin acetate continuous infusion?

Terlipressin acetate continuous infusion is a Small molecule drug developed by BioVie Inc..

Who makes Terlipressin acetate continuous infusion?

Terlipressin acetate continuous infusion is developed by BioVie Inc. (see full BioVie Inc. pipeline at /company/biovie-inc).

Is Terlipressin acetate continuous infusion also known as anything else?

Terlipressin acetate continuous infusion is also known as Terlipressin.

What development phase is Terlipressin acetate continuous infusion in?

Terlipressin acetate continuous infusion is in Phase 2.

Related